1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis
A. Clamp(The Christie NHS Foundation Trust), JA Ledermann(CRUK Lung Cancer Centre of Excellence), Axel Walther, R.S. Kaplan(MRC Clinical Trials Unit at UCL), A. Gentry-Maharaj(MRC Clinical Trials Unit at UCL), S. Sundar(Cancer Research UK Clinical Trials Unit), J.D. Brenton(Cancer Research UK Cambridge Center), C. Sessa(Ospedale Regionale di Bellinzona e Valli), Francesco Schiavone(MRC Clinical Trials Unit at UCL), Alistair Cook(Cheltenham General Hospital), Sarah P. Blagden(Churchill Hospital), Radhika Agarwal(Northampton General Hospital), Agnieszka Michael(University of Surrey), Davide Radice(MRC Clinical Trials Unit at UCL), Iain A. McNeish(Imperial College London), Dearbhaile M. O’Donnell, M.K. Parmar(MRC Clinical Trials Unit at UCL), L.R. Murphy(MRC Clinical Trials Unit at UCL), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust)
Cited by 3
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k